Danaher & the Bioprocessing FDA Approval Process
Former Head of Sales, GE Life Sciences
inpractise.com/articles/danaher-and-the-bioprocessing-fda-approval-process
Danaher & the Bioprocessing FDA Approval Process(July 31, 2024)
Former Head of Sales, GE Life Sciences
Interview Transcript
This is a snippet of the transcript, sign up to read more.
But in terms of the customer, let's say, at the drug discovery phase, are they focusing more on the resins or the media, or are both equally critical?
Equally. Yes, and that's why you have upstream R&D, upstream process development, and similar functions. You run downstream processes in parallel because both are critical elements. You need to ensure they are optimally functional and stable. Stability is key. The company is trying to instill an industrial mindset across the organization. Everyone will benefit by thinking of this as a product, not just fun work in the lab. Both upstream media and downstream resins are equally mission-critical.
This is a snippet of the transcript, sign up to read more.
Related Content
Danaher, Cytiva: Downstream Sales Process
Former Head of Sales, GE Life Sciences
Danaher: Cytiva & the Chromatography Process
Former Head of Sales, GE Life Sciences
Danaher, Sartorius, & an Overview of The Bioprocessing Environment
Former VP of Sales at Pall Corp
Pall, Cytiva & the Bioprocessing Manufacturing Process
Former VP of Sales at Pall Corp
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.